Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Gains from Investment Securities: 2012-2024

Historic Gains from Investment Securities for Ocular Therapeutix (OCUL) over the last 13 years, with Dec 2024 value amounting to $19.9 million.

  • Ocular Therapeutix's Gains from Investment Securities fell 81.98% to $1.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $1.0 million, marking a year-over-year decrease of 81.98%. This contributed to the annual value of $19.9 million for FY2024, which is 23.24% up from last year.
  • According to the latest figures from FY2024, Ocular Therapeutix's Gains from Investment Securities is $19.9 million, which was up 23.24% from $16.1 million recorded in FY2023.
  • In the past 5 years, Ocular Therapeutix's Gains from Investment Securities ranged from a high of $19.9 million in FY2024 and a low of $9.1 million during FY2020.
  • Moreover, its 3-year median value for Gains from Investment Securities was $16.1 million (2023), whereas its average is $16.6 million.
  • Data for Ocular Therapeutix's Gains from Investment Securities shows a peak YoY climbed of 25.01% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows Ocular Therapeutix's Gains from Investment Securities stood at $9.1 million in 2020, then rose by 19.97% to $10.9 million in 2021, then climbed by 25.01% to $13.7 million in 2022, then increased by 18.05% to $16.1 million in 2023, then increased by 23.24% to $19.9 million in 2024.